PSMA PET Response Guided SabR in High Risk Pca

Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose

Trial Details

NCT ID
NCT06044857
Phase
PHASE1
Sponsor
University of Texas Southwestern Medical Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 68-Ga PSMA11
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Pathologically confirmed adenocarcinoma of the prostate (within 180 days of registration) of high risk by national comprehensive cancer network (NC…
  • Age ≥ 18 years.
  • Planned for definitive intent stereotactic ablative radiotherapy (SabR) with integrated dose boost to intra-prostatic tumor and androgen deprivatio…
  • Staging 68Ga PMSA-11 PET -CT or -MRI performed within 90 days of registration and before initiation of anti-androgen or androgen deprivation therap…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →